Manak, Michael S.
Varsanik, Jonathan S.
Hogan, Brad J.
Whitfield, Matt J.
Su, Wendell R.
Joshi, Nikhil
Steinke, Nicolai
Min, Andrew
Berger, Delaney
Saphirstein, Robert J.
Dixit, Gauri
Meyyappan, Thiagarajan
Chu, Hui-May
Knopf, Kevin B.
Albala, David M.
Sant, Grannum R.
Chander, Ashok C.
Article History
Received: 17 April 2017
Accepted: 2 August 2018
First Online: 17 September 2018
Competing interests
: The authors declare the following competing financial interests: M.S.M., J.S.V., M.J.W., W.R.S., N.J., N.S., A.M., D.B., R.J.S., G.D., T.M., H.M.C., K.B.K., G.R.S. and A.C.C.: Cellanyx Diagnostics, stock options. B.J.H.: Cellanyx Diagnostics, consultant stock options. D.M.A.: Genomic Health, speaker; Myriad Genetics, speaker; Cellanyx Diagnostics, stock options; Applied Medical, stock options. The following patents WO2016138041, WO2013075145 and WO2012048269<sup>21,22,26</sup> cover aspects of the technology presented in this paper.